Nipocalimab Dose Selection in Generalized Myasthenia Gravis. [PDF]
CPT Pharmacometrics Syst PharmacolABSTRACT Nipocalimab is a fully human immunoglobulin G (IgG)1 monoclonal antibody (mAb) designed to selectively block the IgG binding site of neonatal fragment crystallizable receptor (FcRn) to inhibit IgG recycling and decrease circulating IgG, including pathogenic IgG autoantibodies (such as antiacetylcholine receptor, anti‐muscle ...
Valenzuela B +8 more
europepmc +3 more sources
Consistent improvement with eculizumab across muscle groups in myasthenia gravis
Annals of Clinical and Translational Neurology, 2020 Objective To assess whether eculizumab, a terminal complement inhibitor, improves patient‐ and physician‐reported outcomes (evaluated using the myasthenia gravis activities of daily living profile and the quantitative myasthenia gravis scale ...
Renato Mantegazza +4 more
doaj +1 more source
Myasthenia Gravis Revealing Hodgkin’s Lymphoma
European Journal of Case Reports in Internal Medicine, 2021 Introduction: Myasthenia gravis is a rare autoimmune disease caused by autoantibodies directed against the synapses of the neuromuscular junction. Patient and methods: We report the case of a young patient with myasthenia gravis associated with Hodgkin ...
Jaouad Yousfi +4 more
doaj +1 more source
Comparison of Clinical Manifestations between Patients with Ocular Myasthenia Gravis and Generalized Myasthenia Gravis [PDF]
Korean Journal of Ophthalmology, 2011 To compare the clinical manifestations between patients with ocular myasthenia gravis and those with generalized myasthenia gravis (MG).The medical records of 71 patients diagnosed with MG between January 1995 and December 2007 were reviewed. Demographics, sensitivities of diagnostic methods, the presence of systemic autoimmune diseases, ophthalmic ...
Roh, Hyun Seok +2 more
openaire +3 more sources
Association of Smoking and Generalized Manifestations of Myasthenia Gravis
Internal Medicine, 2022 Objective Smoking is a known risk factor for the development and progression of autoimmune diseases. Previous studies in ocular myasthenia gravis (MG) patients showed that smoking is associated with the severity of symptoms and progression to generalized MG.
Miyazaki, Yusei +9 more
openaire +3 more sources
Prognosis of Ocular Myasthenia Gravis: Retrospective Multicenter Analysis [PDF]
, 2015 PURPOSE: To calculate the rate and timing of conversion from ocular myasthenia gravis to generalized myasthenia gravis. DESIGN: Retrospective multicenter analysis. SUBJECTS: Patients included in the study were diagnosed with ocular myasthenia gravis
Abusamra, K +4 more
core +1 more source
T-lymphocyte-rich thymoma and myasthenia gravis in a Siberian tiger (Panthera tigris altaica) [PDF]
, 2014 A 10-year-old captive male Siberian tiger (Panthera tigris altaica) presented with acute onset collapse, vomiting and dyspnoea, preceded by a 6-month period of progressive muscle wasting.
A. Routh +31 more
core +1 more source
A phase 3 multicenter, prospective, open-label efficacy and safety study of immune globulin (human) 10% caprylate/chromatography purified in patients with myasthenia gravis exacerbations [PDF]
, 2019 Background: Myasthenia gravis (MG) is an autoimmune disorder affecting neuromuscular transmission. Exacerbations may involve increasing bulbar weakness and/or sudden respiratory failure, both of which can be critically disabling.
Ayguasanosa, J +17 more
core +2 more sources
Neurologijos seminarai, 2022 Myasthenia gravis is a chronic autoimmune neuromuscular disorder typically presenting with variable skeletal muscle fatigue. The most prevalent initial manifestation of myasthenia is ocular myasthenia.
J. Zakaravičiūtė, M. Šerelytė
doaj +3 more sources